Journal
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Volume 51, Issue 6, Pages 646-653Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/00365521.2015.1124286
Keywords
prognosis; hepatoid adenocarcinoma; gastric; Alpha-fetoprotein; stomach
Categories
Ask authors/readers for more resources
Objective The term hepatoid adenocarcinoma (HAC) of the stomach was introduced three decades ago with the observation of high serum alpha-fetoprotein (AFP) levels in some gastric adenocarcinoma patients. This very rare gastric cancer patient subgroup is likely frequently misdiagnosed. Material Two patients who were recently diagnosed with HAC of the stomach at our institution are presented. We also performed a structured literature search and reviewed pertinent articles to provide knowledge to improve the proper identification, diagnosis and management of patients with gastric HAC. Results HAC is a rare subgroup of gastric carcinoma with poor prognosis. Clinical management of this population may be challenging. The scientific literature is largely based on very small patient series or case reports, and the evidence for proper decision making and management is considered weak. Conclusion All physicians involved in the diagnosis and treatment of patients with gastric cancer should pay attention to this rare subgroup to improve identification.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available